Design Therapeutics Q4 2024 net loss $13.7M; cash $245.5M; FA and FECD trials advancing

Design Therapeutics, Inc.

Net loss of $13.7M for Q4 2024 and $49.6M for full year 2024; R&D expense $44.4M, G&A $18.0M.
Cash, equivalents and securities $245.5M as of Dec 31, 2024; expected funding into 2029.
FA program: Phase 1 single ascending dose trial of DT-216P2 initiated; patient dosing expected mid-2025.
FECD program: DT-168 Phase 1 dosing complete; data on track for H1 2025; observational study enrolled ~250 patients.
DM1 development candidate selection expected in 2025; HD preclinical work ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.